Ambitious Schedule For OTC Monograph Updates On FDA Unified Agenda
This article was originally published in The Tan Sheet
Executive Summary
Nearly two-thirds of FDA’s planned regulatory actions for the consumer health segment would update the OTC drug monograph, including changes to pediatric cough/cold labeling, acetaminophen dosing, oral care products with benzocaine and labeling for some laxatives.
You may also be interested in...
House Appropriators Watch Clock On OTC Cough/Cold, Sunscreen Monographs
House appropriators recommend FDA in June publish a proposed rule for safety and efficacy of cough/cold OTCs in pediatric populations They also direct FDA by December to complete its review of the remaining sunscreen ingredient safety and effectiveness TEA submissions.
In Brief: FTC, FDA Enforcement; Insider Trading On NBTY Sale; Comment Period On Label Changes
FTC says Pure Green Coffee perks false claims; NBTY shareholder settles insider trading case; scientific citations trigger warning letter; supplement labels must detail plant source; scientific citations trigger warning; and more news In Brief.
In Brief: laxatives warning, FTC settlement, ChromaDex inks 5LINX deal
Sodium phosphate laxatives linked to SAERs; FTC scrutinizes personalized supplement claims; NAD refers Xlear LLC to FTC; ChromaDex inks marketing deal with 5LINX; CVS launches vitamin sales, info hub on its website; Star Scientific shareholder suit proceeds.